Cullinan reports Q3 2026 results, flags December CLN-978 data and zipalertinib NDA progressNov 10Quarterly updateBlossomHill TherapeuticsCLN-978
Cullinan and Taiho start FDA review of zipalertinib combo for first-line lung cancerOct 1Clinical readoutCLN-049CLN-978Updated
Cullinan reports Q2 2026 results, outlines T cell engager trial timelinesAug 6Quarterly updateCullinan Therapeutics Inc.